RGC (Regencell Bioscience Holdings) Debt-to-Asset : 0.00 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RGC Regencell Bioscience Holdings Ltd RGC
30 GF Score
Price $5.51
! 2 Warning Signs
View Full Analysis

What is Regencell Bioscience Holdings Debt-to-Asset?

Regencell Bioscience Holdings RGC +0.18% 30 Debt-to-Asset is 0.00 as of Dec. 2025. GuruFocus rates RGC with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Regencell Bioscience Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $0.00 Mil. Regencell Bioscience Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $0.00 Mil. Regencell Bioscience Holdings's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2025 was $3.01 Mil. Regencell Bioscience Holdings's debt to asset for the quarter that ended in Dec. 2025 was 0.00.

Regencell Bioscience Holdings  (NAS:RGC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Regencell Bioscience Holdings Debt-to-Asset Related Terms

Regencell Bioscience Holdings Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Regencell Bioscience Holdings's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regencell Bioscience Holdings Debt-to-Asset Chart

Regencell Bioscience Holdings Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Debt-to-Asset
Get a 7-Day Free Trial 10.83 0.04 0.04 0.01 0.10

Regencell Bioscience Holdings Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.01 0.00 0.10 0.00

RGC vs SUPN, BCRX, PBH: Debt-to-Asset Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regencell Bioscience Holdings Debt-to-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's Debt-to-Asset falls into.


RGC
30GF Score
Regencell Bioscience Holdings Ltd RGC
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regencell Bioscience Holdings Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Regencell Bioscience Holdings's Debt-to-Asset for the fiscal year that ended in Jun. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.313 + 0.232) / 5.756
=0.09

Regencell Bioscience Holdings's Debt-to-Asset for the quarter that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 0) / 3.013
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.00 mean?
Regencell Bioscience Holdings (RGC) has a Debt-to-Asset of 0.00 as of Dec. 2025. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Regencell Bioscience Holdings and its competitors.
Is Regencell Bioscience Holdings' Debt-to-Asset too high?
Regencell Bioscience Holdings' current Debt-to-Asset is 0.00. Overall, Regencell Bioscience Holdings has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Regencell Bioscience Holdings' Debt-to-Asset compare to SUPN and BCRX?
Regencell Bioscience Holdings' Debt-to-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Drug Manufacturers company?
A good Debt-to-Asset depends on the Drug Manufacturers industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Regencell Bioscience Holdings and its competitors. Regencell Bioscience Holdings's current Debt-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regencell Bioscience Holdings stock overvalued right now?
Regencell Bioscience Holdings (RGC) has a current Debt-to-Asset of 0.00. The current Debt-to-Asset is 0.00. Regencell Bioscience Holdings' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Regencell Bioscience Holdings (RGC), the current Debt-to-Asset is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regencell Bioscience Holdings Business Description

Address 29 Leighton Road, 9th Floor, Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
30GF Score

Get the complete analysis for RGC

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.51
Price